Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...

Wuxi International Life-Science Innovation Campus, or iCampus, signed a strategic cooperation agreement with the Hong Kong ...

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its ...

This month IssueVoter and BillTrack50 take a look at the BIOSECURE Act, a significant escalation in efforts to restrict ...

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

三氟化硼（CAS 7637-07-2）行业调研报告聚焦三氟化硼（CAS 7637-07-2）市场并重点对该市场的历史与预测期市场规模做出了统计与预测，报告显示，2023年全球三氟化硼（CAS 7637-07-2）市场规模为 ...

As the Chinese contract manufacturer awaits the U.S. Senate’s consideration of the BIOSECURE Act, it has added 800 new ...

U.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as ...

In addition, WuXi AppTec drives sustainability by participating in ambitious global frameworks. In 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions, and ...

and Complete Genomics); contract-based research for drug development (WuXi) and biomanufacturing that synthesizes biologics and active pharmaceutical ingredients to produce drugs at scale (WuXi).

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, ...